No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Standard BioTools Up 28%, on Pace for Largest Percent Increase Since May 2022 -- Data Talk
Intra-Cellular Therapies, Standard BioTools, SI-BONE And Other Big Stocks Moving Higher On Monday
Standard BioTools Shares Are Trading Higher After the Company Announced Preliminary Q4 and FY24 Financial Results.
Standard BioTools Reports 2024 Revenue Achievements and Plans
Express News | Standard BioTools Inc: Expects Q4 2024 Revenue of Approximately $46.5 Mln
Press Release: Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2024 Revenue